ClinicalTrials.gg
RecruitingNCT07477509Updated May 26, 2026

Northwestern Neuromuscular Disease Biorepository

An observational study in Neuromuscular Diseases (NMD), sponsored by Northwestern University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Northwestern University · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
2,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 120 studies in Neuromuscular Diseases with a site in United States — 29 open to participants now, 39 under way, 4 of them phase 3. Neuromuscular Diseases · United States.

Planned enrollment
2nd of 46
2,500 · median 82
Started
2026
with 9 others
Observational
46 of 120
17 open now
Primary completion
2050-03
later than 37 of 38 live
Registered
115th of 120
by date

Among the 120 studies in Neuromuscular Diseases with a site in United States, this one is the 2nd largest by planned enrollment of the 46 observational ones that give a count, is one of 10 that started in 2026, is one of 46 observational ones, reaches primary completion later than 37 of the 38 other live ones, and was the 115th registered.

Neuromuscular Diseases

361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.

Browse Neuromuscular Diseases studies →

Open to participants now

29 of the 120 studies in Neuromuscular Diseases with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Neuromuscular Diseases with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this research is to collect clinical data and tissue samples from adult patients with neuromuscular disease cared for at the Northwestern Memorial Hospital neuromuscular clinic (Lavin Building, 19th floor).

This study has the following aims:

Aim 1: To consent a large cohort of adult study participants with neuromuscular disorders, including but not limited to motor neuron diseases, neuropathies, neuromuscular junction disorders, and myopathies for participation in the biorepository and to collect longitudinal data on their clinical disease phenotypes.

Aim 2: To obtain and store biological samples from biorepository study participants, including whole blood, plasma, serum, peripheral blood mononuclear cells [PBMCs], skin biopsies, and cerebrospinal fluid.

Aim 3: To develop a data-sharing process to provide de-identified biorepository participant clinical data and samples to partnered investigators to expedite discovery in neuromuscular disease diagnosis and treatment.

Read the detailed description

Northwestern University and the associated Northwestern Memorial Hospital serve a nexus of clinical care and translational research in neuromuscular disease. A significant opportunity exists within the division to develop a robust Neuromuscular Disease Biorepository (NDB) in which carefully-phenotyped patient biofluid samples are catalogued and made readily available to partnered basic and translational scientists both within and outside of the Northwestern academic community.

The overarching hypothesis underpinning the Northwestern Disease Biorepository is that longitudinally sampled participant biosamples paired to refined clinical and paraclinical phenotypic data will accelerate basic and translational scientific discovery both locally at Northwestern and ultimately in the larger research community. This is imperative in the world of neuromuscular disease, where effective treatments are emerging yet all too rare, and understanding of disease mechanisms is still in a fledgling state for most conditions.

Procedures:

A possible participant will be identified by minimal risk screening activities by the biorepository principal investigator or delegated co-investigators. Screening activities include routine chart review including clinical notes, laboratory and radiologic investigations, pathology reports, and completed genetic testing. After a possible participant has been identified, they will be consented by a biorepository investigator using the IRB-approved informed consent form (ICF). Consented participants will then complete a clinical data questionnaire (IRB-approved data collection tool) specifically designed to allow biorepository investigators to rapidly and accurately phenotype the wide-spectrum of neuromuscular disease encountered in routine clinical care. Blood samples will be obtained by trained repository staff. Blood samples will be routinely processed into plasma and serum; additional processing for RNA extraction and peripheral blood mononuclear cells will be completed at the investigator's discretion. Cerebrospinal fluid (CSF) sampling is optional; Lumbar puncture will be completed by a qualified investigator as described in the NU IRB protocol. CSF samples can also be obtained in the event of an indicated lumbar puncture during routine clinical care or as an adjunct to other ongoing studies within the NU/NM neuromuscular division where permitted by the specific study protocol. Clinical data questionnaires and samples will be obtained every six months where feasible.

To obtain access to biorepository samples, an interested research group must contact a biorepository investigator and provide a scientific proposal describing their hypotheses and specific use of provided biosamples. Requests will be sent to the PI Dr. Donaghy at Ryan.Donaghy@nm.org. Requests will be approved by the protocol detailed in the Biorepository Scientific Validity Review Committee Standard Operating Procedure (SVRC SOP). Unless a requesting research group has already received an IRB approved proposal that allows for sharing of protected health information (PHI) by HIPAA rules, research samples will be provided without any of the 18 established PHI content as described in the SOP. The provision of non-PHI-containing research materials to requesting researchers is approved by Northwestern University-IRB.

03

Conditions studied

  • Neuromuscular Diseases (NMD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Neuromuscular Diseases

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing evaluation for or diagnosed with a neuromuscular disorder, including but not restricted to motor neuron diseases (MNDs), neuropathies, neuromuscular junction disorders, and myopathies as a patient under the care of a provider in the Northwestern Neuromuscular Division
  • Provision of signed and dated form personally or via legally authorized representative (LAR) [SOP: HRP-013] in accordance with Good Clinical Practice (GCP), International Conference on Harmonization (ICH), and local regulations.

Exclusion criteria

Exclusion Criteria:

  • History of a bleeding disorder or current treatment with anticoagulants (e.g., Coumadin, heparin) in participating study participants that would preclude collection of CSF or skin for these sub-studies.
  • History of keloid formation for study participants who will undergo skin biopsy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
2,500 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Biospecimen Samples

    This is a longitudinal registry of biofluid samples paired to categorized clinical data ultimately used to provide sample to partnered basic scientists and accelerate discovery in neuromuscular medicine.

    Time frame: 50 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Mar 2050, 286 months after the start.

Of 64 non-industry observational studies under Neuromuscular Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 114. This study's planned 286 months is above that.

Counting every sponsor, half of 70 studies reached it within 37 months; a quarter within 12 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 17, 2026
StartActual
May 1, 2026
Primary completionEst.
Mar 2050
CompletionEst.
Mar 2050
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07477509
Responsible party
Ryan Donaghy (Assistant Professor of Neurology, Northwestern University) — Principal investigator
First posted
Mar 17, 2026
Start date
May 1, 2026
Primary completion
Mar 2050 (estimated)
Completion
Mar 2050 (estimated)
Last update
May 26, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion